MétaCan
Menu
Back to cohort
Record W4404911856 · doi:10.1097/ju.0000000000004348

Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause Mortality

2024· article· en· W4404911856 on OpenAlexaffabout
Ranjeeta Mallick, Daniel I. McIsaac, Luke T. Lavallée, Bimal Bhindi, Daniel Y.C. Heng, Lori Wood, Ricardo Rendon, Simon Tanguay, Anthony Finelli, Rahul Bansal, Aly‐Khan A. Lalani, Naveen S. Basappa, Miles Mannas, Jasmir G. Nayak, Georg A. Bjarnason, Jean‐Baptiste Lattouf, Frédéric Pouliot, Patrick O. Richard, Camilla Tajzler, Rodney H. Breau

Bibliographic record

VenueThe Journal of Urology · 2024
Typearticle
Languageen
FieldMedicine
TopicRenal cell carcinoma treatment
Canadian institutionsUniversité de MontréalSunnybrook Health Science CentreUniversité LavalManitoba HealthCentre Hospitalier Universitaire de SherbrookeUniversity of British ColumbiaUniversity of AlbertaUniversity of ManitobaJuravinski Cancer CentreMcMaster UniversityQueen Elizabeth II Health Sciences CentreUniversity of OttawaMcGill UniversityUniversity of CalgaryPrincess Margaret Cancer CentreHealth Sciences CentreUniversity Health NetworkOttawa HospitalUniversity of TorontoDalhousie University
Fundersnot available
KeywordsMedicineRenal cell carcinomaOncologyInternal medicineCancerCarcinomaKidney cancer

Abstract

fetched live from OpenAlex

PURPOSE: Postoperative prognostic tools allow for improved prediction of future recurrence risk, patient counseling, assessment of eligibility for adjuvant treatments, and appropriate follow-up surveillance. The purpose of this analysis was to validate prognostic models for patients with kidney cancer. MATERIALS AND METHODS: The Canadian Kidney Cancer information system is a prospective cohort of patients managed at 14 institutions since January 1, 2011, to present. The Canadian Kidney Cancer information system was used to assess 15 predictive models for kidney cancer recurrence, 6 for cancer-specific mortality, and 4 for all-cause mortality in patients with a solitary, nonmetastatic kidney tumor treated with surgery (partial or radical nephrectomy). Discrimination was measured using C statistics, 5-year calibration plots for calibration, and decision curve analysis at 5 years after surgery for net benefit when considering adjuvant therapy. RESULTS: Seven thousand one hundred seventy-four patients were included. For kidney cancer recurrence, C statistics ranged from 0.62 to 0.83, depending on whether the model was derived and applied to all patients without further stratification, specific risk groups, or specific histologic subtypes. Cancer-specific mortality models had C statistics ranging from 0.60 to 0.89 and all-cause mortality models from 0.60 to 0.73. Using decision curve analysis in patients with clear-cell renal cell carcinoma, the best models for choosing adjuvant therapy to prevent recurrence and cancer-related death were the Mayo Clinic prediction models. CONCLUSIONS: Model performance varied considerably with some suitable for clinical use. If using prediction models to select adjuvant therapy, the Mayo Clinic models were best when applied to a large contemporary cohort of Canadian patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.030
metaresearch head score (Gemma)0.063
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.037
Threshold uncertainty score0.160

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0300.063
Meta-epidemiology (narrow)0.0020.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0030.002
Science and technology studies0.0010.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.130
GPT teacher head0.347
Teacher spread0.217 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueThe Journal of UrologySame topicRenal cell carcinoma treatmentFrench-language works237,207